↓ Skip to main content

A Randomized, Double-Blind and Placebo-Controlled Study of a Ganoderma lucidum Polysaccharide Extract in Neurasthenia

Overview of attention for article published in Journal of Medicinal Food, March 2005
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
8 news outlets
twitter
11 X users
patent
2 patents
facebook
3 Facebook pages
googleplus
1 Google+ user
video
7 YouTube creators

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
91 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Randomized, Double-Blind and Placebo-Controlled Study of a Ganoderma lucidum Polysaccharide Extract in Neurasthenia
Published in
Journal of Medicinal Food, March 2005
DOI 10.1089/jmf.2005.8.53
Pubmed ID
Authors

Wenbo Tang, Yihuai Gao, Guoliang Chen, He Gao, Xihu Dai, Jinxian Ye, Eli Chan, Min Huang, Shufeng Zhou

Abstract

Ganoderma lucidum has been widely used to treat various diseases, including cancer, diabetes, and neurasthenia in many Asian countries. This randomized, double-blind, placebo-controlled parallel study aimed to investigate the efficacy and safety of a polysaccharide extract of G. lucidum (Ganopoly) in Chinese patients with neurasthenia. One hundred thirty-two patients with neurasthenia according to the diagnosis criteria of the 10th International Classification of Diseases were included in this study. Written consents were obtained from the patients, and the study was conducted in accordance with Good Clinical Practice guidelines. Patients were randomized to receive Ganopoly or placebo orally at 1,800 mg three times a day for 8 weeks. Efficacy assessments comprised the Clinical Global Impression (CGI) improvement of severity scale and the Visual Analogues Scales for the sense of fatigue and well-being. In 123 assessable patients in two treatment groups at the end of the study, Ganopoly treatment for 8 weeks resulted in significantly lower scores after 8 weeks in the CGI severity score and sense of fatigue, with a respective reduction of 15.5% and 28.3% from baseline, whereas the reductions in the placebo group were 4.9% and 20.1%, respectively. The score at day 56 in the sense of well-being increased from baseline to 38.7% in the Ganopoly group compared with 29.7% in the placebo group. The distribution of the five possible outcomes from very much improved to minimally worse was significantly different (X (2) = 10.55; df = 4; P = .0322) after treatment with Ganopoly or placebo. There was a percentage of 51.6% (32 of 62) in the Ganopoly group rated as more than minimally improved compared with 24.6% (15 of 61) in the placebo group (X (2) = 9.51; df = 1; P = .002). Ganopoly was well tolerated in the study patients. These findings indicated that Ganopoly was significantly superior to placebo with respect to the clinical improvement of symptoms in neurasthenia.

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Singapore 1 1%
Unknown 90 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 18 20%
Researcher 14 15%
Student > Bachelor 12 13%
Other 8 9%
Student > Doctoral Student 7 8%
Other 8 9%
Unknown 24 26%
Readers by discipline Count As %
Medicine and Dentistry 18 20%
Agricultural and Biological Sciences 14 15%
Psychology 5 5%
Nursing and Health Professions 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 15 16%
Unknown 31 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 72. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2023.
All research outputs
#593,061
of 25,464,544 outputs
Outputs from Journal of Medicinal Food
#81
of 1,619 outputs
Outputs of similar age
#650
of 76,767 outputs
Outputs of similar age from Journal of Medicinal Food
#1
of 11 outputs
Altmetric has tracked 25,464,544 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,619 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,767 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.